A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?
A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.
ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice
Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.